Taurohyodeoxycholic acid

Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027) -induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula[1][2][3][4].

Product Specifications

CAS Number

[2958-04-5]

Product Name Alternative

AG-013736

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

COX; Endogenous Metabolite; Glutathione Peroxidase; Interleukin Related; TNF Receptor

Type

Natural Products

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Neurological Disease; Inflammation/Immunology; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/taurohyodeoxycholic-acid.html

Concentration

10mM

Purity

99.73

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@@]12[C@]3([H])[C@](C[C@@H]([C@]1([H])C[C@@H](CC2)O)O)([H])[C@@]4([H])[C@](CC3)([C@@](CC4)([H])[C@H](C)CCC(NCCS(=O)(O)=O)=O)C

Molecular Formula

C26H45NO6S

Molecular Weight

499.70

Precautions

H302, H315, H319, H335

References & Citations

[1]Roda A, et, al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology. 1998 Feb;27 (2) :520-5.|[2]Carubbi F, et, al. Comparative cytotoxic and cytoprotective effects of taurohyodeoxycholic acid (THDCA) and tauroursodeoxycholic acid (TUDCA) in HepG2 cell line. Biochim Biophys Acta. 2002 Jan 30;1580 (1) :31-9.|[3]Zheng N, et al. Astragalus polysaccharide attenuates nonalcoholic fatty liver disease through THDCA in high-fat diet-fed mice. J Ethnopharmacol. 2024 Feb 10;320:117401. |[4]Lv L, et al. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Life Sci. 2023 Apr 1;318:121501.|[5]Roda A, et al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology. 1998 Feb;27 (2) :520-5. |[6]He J, et al. Protective effect of taurohyodeoxycholic acid from Pulvis Fellis Suis on trinitrobenzene sulfonic acid induced ulcerative colitis in mice. Eur J Pharmacol. 2011 Nov 16;670 (1) :229-35.